Skip to content
value.today

Neuraptive Therapeutics, Inc.

🇺🇸 Louisville, Colorado, USABiotechnologyFounded 2017
Total raised
$30 M
2 rounds on record
Latest round
$19 M
Sep 2022
First round on record
Dec 2018
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Neuraptive Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2022$19 MNo. 2$10 to $50 million

Neuraptive Therapeutics, Inc.: Raise no. 2, Sep 2022

Investors in this round

71 investors had bought by the notice of Oct 14, 2022: 71 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$19 M of $38 M offered; $19 M still to sell
Smallest investment taken
$25,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,125,740
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Pennsylvania

People named in the notice

  • Evan S Tzanis · Executive Officer
  • Robert S Radie · Executive Officer, Director
  • David S Jackson · Director
  • David S Pierce · Director
  • Greg S Parekh · Director
  • Ivan S Gergel · Director
  • Randy S Hubbell · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “Placement Agent Fee”

Signed by Robert S. Radie, Chairman and CEO. Newest notice filed Oct 14, 2022. Read the notice at the SEC.

equity, optionsSEC
Dec 2018$10 MNo. 1$10 to $50 million

Neuraptive Therapeutics, Inc.: Raise no. 1, Dec 2018

Investors in this round

5 investors had bought by the notice of Apr 17, 2019: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $13 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Jackson · Executive Officer, Director
  • Gino DiSciullo · Director
  • Greg Parekh · Director
  • Ivan Gergel · Director
  • Randy Hubbell · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David M. Jackson, Chief Executive Officer. Newest notice filed Apr 17, 2019. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Neuraptive Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2022).

    SEC Form D · Oct 2022

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2022

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Neuraptive Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Neuraptive Therapeutics, Inc.
NameRoleNamed in
Evan S TzanisExecutive officerOct 2022
Robert S RadieExecutive officerOct 2022
David JacksonExecutive officerApr 2019
David S JacksonDirectorOct 2022
David S PierceDirectorOct 2022
Greg S ParekhDirectorOct 2022
Ivan S GergelDirectorOct 2022
Randy S HubbellDirectorOct 2022
Robert S RadieDirectorOct 2022
David JacksonDirectorApr 2019
Gino DiSciulloDirectorApr 2019
Greg ParekhDirectorApr 2019
Ivan GergelDirectorApr 2019
Randy HubbellDirectorApr 2019